Digitoxose | 7584-71-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Digitoxose
• 英文别名: Digitoxose, D-；3,4,5-trihydroxyhexanal
• CAS: 7584-71-6
• 化学式: C₆H₁₂O₄
• 分子量: 148.159
• InChiKey: JWFRNGYBHLBCMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Partial esters of epoxy containing compounds and related halogen containing polymer compositions
  申请人：ELF ATOCHEM NORTH AMERICA, INC.

  公开号：EP0553400A1

  公开（公告）日：1993-08-04

  The present invention relates to a partial ester derived from the reaction product of an oxirane containing acid or derivative thereof, and a reactive hydroxyl compound selected from the group consisting of diols, triols, di-diols and 1,4-dihydroxy butane and a halogen containing polymer compositon thereof. The oxirane compound can be derived from the group consisting of epoxidized vegetable oil, epoxidized fish oil, an aliphatic or arylaliphatic containing craboxyl compound having an oxirane group in the aliphatic chain.

  本发明涉及一种部分酯，由含环氧乙烷的酸或其衍生物与选自二元醇、三元醇、二元醇和 1,4-二羟基丁烷的活性羟基化合物及其含卤聚合物复合物的反应产物衍生而成。环氧乙烷化合物可以来自环氧化植物油、环氧化鱼油、脂肪链中含有环氧乙烷基团的脂肪族或芳基脂肪族羧基化合物。
• Process for introducing an amino group on the 14-position of a steroid nucleus
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0863149A1

  公开（公告）日：1998-09-09

  The present invention relates to oligosaccharide-containing 14-aminosteroid compounds and the pharmaceutically-acceptable acid salts or esters thereof of the general formula: wherein a) R1 is (i) COOR5, where    R5 is hydrogen, a 1-6 carbon lower alkyl ; a 1-6 carbon lower alkyl substituted by an amino group; an arylalkyl or heteroarylalkyl or a carbocyclic ring, or (ii) CHR6OH, where    R6 is a hydrogen atom or 1-6 carbon lower alkyl group, or (iii) COR''', where R''' is hydrogen; 1-6 carbon lower alkyl; 1-6 carbon lower alkyl substituted amino; amino or dialkylamino; and b) R2 is -NR7R8, where    R7 and R8, which may be the same or different, are hydrogen atoms or a 1-6 carbon lower alkyl ; and c) R3 is (i) an oligosaccharide sugar residue having the following structure: where R9 is hydrogen; methyl; hydroxy; carboxy; acetoxy; arylalkyloxy; heteroarylalkyloxy or benzoxy; R10 is hydrogen; methyl; carboxy; acetoxy; arylalkyloxy; heteroarylalkyloxy; benzoxy or hydroxy; R11 is oxygen; wherein further when R11 is a substituent on the terminal monosaccharide sugar residue; R11 is OH; methyl; acetoxy; arylalkyloxy; heteroarylalkyloxy; and R12 is a hydrogen; methyl; methylhydroxymethyl; or acetoxymethyl; or (ii) an oligosaccharide sugar residue having the following structure: where R14 and R15, which may be the same or different, are hydrogen; 1-6 carbon lower alkyl; heteroarylalkyl; arylalkyl; heteroaryl or aryl; R17 can be hydrogen; hydroxy; acetoxy or benzoxy; R18 and R19 are hydroxy; acetoxy and benzoxy; or (iii) an oligosaccharide residue having the following structure: where R14 and R15, which may be the same or different, are hydrogen; 1-6 carbon lower alkyl; heteroaryl alkyl; arylalkyl; heteroaryl or aryl; R14a is oxygen; wherein further when R14a is a substituent on the terminal monosaccharide sugar residue; R14a must be hydroxy; methyl; acetoxy; arylalkyloxy or heteroarylalkyloxy; and d) R4 is (i) OH, or (ii) H, or (iii) OR13, where R13 is a monosaccharide sugar residue; acetoxy; benzoxy; arylalkyl or heteroarylalkyl; and e) Z is (i) -CH-, where a and b are single bonds, or (ii) =C, where either a or b is a double bond. The present invention also relates to a process for introducing an amino group at the 14-position on a steroid nucleus wherein said amino group is diasteroselectively introduced onto the 14-position of the steroid nucleus via an iodoisocyanate addition comprising the steps of: a) adding the iodoisocyanate to the 14-15 position double bond on the steroid nucleus; and b) dehalogenation; and c) isocyanate conversion to the amine moiety on the 14-position of the steroid nucleus.

  本发明涉及通式如下的含寡糖的 14-氨基甾化合物及其药学上可接受的酸盐或酯： 其中 a) R1 是 (i) COOR5，其中 R5 是氢、1-6 碳低烷基、被氨基取代的 1-6 碳低烷基、芳烷基、杂芳烷基或碳环基，或 (ii) CHR6OH，其中 R6 是氢原子或 1-6 碳低烷基，或 (iii) COR'''，其中 R'''是氢；1-6 碳低烷基；1-6 碳低烷基取代的氨基；氨基或二烷基氨基；和 b) R2 是-NR7R8，其中 R7 和 R8（可以相同或不同）是氢原子或 1-6 碳低碳烷基；以及 c) R3 是 (i) 具有以下结构的寡糖残基： 其中 R9 是氢；甲基；羟基；羧基；乙酰氧基；芳烷氧基；杂芳烷氧基或苯氧基； R10 是氢；甲基；羧基；乙酰氧基；芳烷氧基；杂芳烷氧基；苯氧基或羟基； R11 是氧；其中，当 R11 是末端单糖糖残基上的取代基时，R11 是 OH；甲基；乙酰氧基；芳基烷氧基；杂芳基烷氧基；以及 R12 是氢；甲基；甲基羟甲基；或乙酰氧甲基；或 (ii) 具有以下结构的寡糖残基： 其中 R14 和 R15（可以相同或不同）是氢；1-6 碳低烷基；杂芳烷基；芳烷基；杂芳基或芳基；R17 可以是氢；羟基；乙酰氧基或苯氧基；R18 和 R19 是羟基；乙酰氧基和苯氧基；或 (iii) 具有以下结构的寡糖残基： 其中 R14 和 R15（可以相同或不同）是氢；1-6 碳低级烷基；杂芳基烷基；芳烷基；杂芳基或芳基；R14a 是氧；其中当 R14a 是末端单糖糖残基上的取代基时，R14a 必须是羟基；甲基；乙酰氧基；芳烷氧基或杂芳基烷氧基；以及 d) R4 是 (i) OH，或 (ii) H，或 (iii) OR13，其中 R13 是单糖糖残基；乙酰氧基；苯氧基；芳烷基或杂芳基；和 e) Z 是 (i) -CH-，其中 a 和 b 为单键，或 (ii) =C，其中 a 或 b 为双键。 本发明还涉及一种在类固醇核的 14 位上引入氨基的工艺，其中所述氨基是通过碘异氰酸酯加成反应，双向选择地引入类固醇核的 14 位上，包括以下步骤： a) 将碘异氰酸酯加到类固醇核的 14-15 位双键上；以及 b) 脱卤；以及 c) 将异氰酸酯转化为甾体核 14 位上的胺分子。
• Gastric acid secretion
  申请人：PHYTOPHARM PLC

  公开号：EP1099444A1

  公开（公告）日：2001-05-16

  The present application relates to the reduction of gastric acid secretion in animals including humans; to methods of treating conditions or disorders associated with or exacerbated by gastric acid secretion; to pharmaceutical compositions useful in carrying out such methods; and to the use of certain extracts and compounds in the treatment of human and non-human animals, generally mammals.

  本申请涉及减少包括人类在内的动物的胃酸分泌；涉及治疗与胃酸分泌相关或因胃酸分泌而加重的病症或紊乱的方法；涉及有助于实施此类方法的药物组合物；涉及在治疗人类和非人类动物（一般为哺乳动物）时使用某些提取物和化合物。
• Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
  申请人：ENGENE, INC.

  公开号：US10456481B2

  公开（公告）日：2019-10-29

  Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

  本文提供了壳聚糖衍生物纳米粒子，包括用阳离子氨基酸和亲水多元醇官能化的壳聚糖；以及制造和使用这种纳米粒子的方法，例如用于体内基因递送。
• Antifungal compounds
  申请人：President and Fellow of Harvard College

  公开号：US10793590B2

  公开（公告）日：2020-10-06

  Compounds of formula (I) or formula (II), compositions and methods useful for treating and/or preventing a fungal infections are provided. wherein the substituents are as defined in the appended claims.

  本发明提供了式(I)或式(II)化合物、用于治疗和/或预防真菌感染的组合物和方法。 其中，取代基如所附权利要求中所定义。